Agios Pharmaceuticals Stock Forecast, Price & News

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AGIO stock has decreased by 2.0% and is now trading at $40.07.
View which stocks have been most impacted by COVID-19.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agios Pharmaceuticals.

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Agios Pharmaceuticals.

Agios Pharmaceuticals will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.36) by $0.05. The biopharmaceutical company earned $37.30 million during the quarter, compared to analyst estimates of $37.17 million. Agios Pharmaceuticals had a negative net margin of 182.49% and a negative return on equity of 59.71%. The firm's quarterly revenue was up 42.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.87) EPS.
View Agios Pharmaceuticals' earnings history.

13 brokerages have issued 1 year price targets for Agios Pharmaceuticals' shares. Their forecasts range from $46.00 to $82.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 69.7% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals.

Agios Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totaling 6,930,000 shares, an increase of 14.7% from the September 15th total of 6,040,000 shares. Based on an average daily trading volume, of 596,200 shares, the days-to-cover ratio is presently 11.6 days.
View Agios Pharmaceuticals' Short Interest.

Some companies that are related to Agios Pharmaceuticals include Mirati Therapeutics (MRTX), Teva Pharmaceutical Industries (TEVA), Ascendis Pharma A/S (ASND), CureVac B.V. (CVAC), Jazz Pharmaceuticals (JAZZ), Galapagos (GLPG), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Perrigo (PRGO), United Therapeutics (UTHR), Bausch Health Companies (BHC) and Blueprint Medicines (BPMC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.55%), Peregrine Capital Management LLC (0.24%), BNP Paribas Arbitrage SA (0.18%), State of New Jersey Common Pension Fund D (0.08%), WINTON GROUP Ltd (0.08%) and DekaBank Deutsche Girozentrale (0.05%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, Scott Biller and Steven L Hoerter.
View institutional ownership trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Peregrine Capital Management LLC, and Parallel Advisors LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden.
View insider buying and selling activity for Agios Pharmaceuticals.

AGIO stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., DekaBank Deutsche Girozentrale, WINTON GROUP Ltd, State of New Jersey Common Pension Fund D, Arthur M. Cohen & Associates LLC, Pacer Advisors Inc., and Nisa Investment Advisors LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $40.07.

Agios Pharmaceuticals has a market capitalization of $2.77 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 536 workers across the globe.

The official website for Agios Pharmaceuticals is www.agios.com.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]